• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/11/21 2:04:18 PM ET
    $OPNT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPNT alert in real time by email
    SC 13G/A 1 opnt-sc13ga_123120.htm AMENDMENT TO FORM SC 13G
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

    Opiant Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common stock, par value $0.001 per share

    (Title of Class of Securities)

     

    683750103

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     

    ☐

    Rule 13d-1(b)

     

    ☒

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

      

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 683750103   Page 2 of 8

     

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0%

     

    12

    TYPE OF REPORTING PERSON

    IA, PN

     

     

     

     

     

     

     

     

     

    CUSIP No. 683750103   Page 3 of 8

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN:  82-2105101

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0%

     

    12

    TYPE OF REPORTING PERSON

    PN

     

     

     

     

     

     

     

     

     

    CUSIP No. 683750103   Page 4 of 8

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN:  82-2086430

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0%

     

    12

    TYPE OF REPORTING PERSON

    OO

     

     

     

     

     

     

     

     

     

    CUSIP No. 683750103   Page 5 of 8

     

    Item 1(a).

     

    Name of Issuer:

    Opiant Pharmaceuticals, Inc (the “Issuer”)

     

     

     

     

    Item 1(b).

     

    Address of Issuer’s Principal Executive Offices:

    233 Wilshire Blvd, Suite 280
    Santa Monica, CA 90401

     

    Item 2(a).  

    Name of Person Filing:  

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP, Altium Capital Management, LLC, and Altium Growth GP, LLC. Altium Growth Fund, LP is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, Altium Growth Fund, LP. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, Altium Growth Fund, LP.

      

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement. 

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

                                                     
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
        The address of the principal business office of each of the reporting persons is 152 West 57 Street, FL 20, New York, NY 10019
         
    Item 2(c).   Citizenship:
        See Item 4 on the cover page(s) hereto.
         
    Item 2(d).   Title of Class of Securities:
        Common stock, par value $0.001 per share (“Common Stock”)
         
    Item 2(e).   CUSIP Number: 683750103
         
    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

       

     

     

     

    CUSIP No. 683750103   Page 6 of 8

      

     

    (c)

    ☐

    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

     

     

     

     

    (d)

    ☐

    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

     

     

     

     

    (e)

    ☐

    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     

    (f)

    ☐

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

     

     

     

     

    (g)

    ☐

    A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);

     

     

     

     

     

    (h)

    ☐

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

     

    (i)

    ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

     

     

     

     

    (j)

    ☐

    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    Item 4.

    Ownership.

     

     

     

    As of the close of business on December 31, 2020, each of the Reporting Persons have no beneficial ownership of the Issuer’s Common Stock.

     

     

     

     

    CUSIP No . 683750103   Page 7 of 8

      

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

     

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒

     

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable

     

     

    Item 8.

    Identification and Classification of Members of the Group.

     

    Not applicable

     

     

    Item 9.

    Notice of Dissolution of Group.

     

    Not applicable

     

     

    Item 10.

    Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Dated:

    February 10, 2021

     

     

     

     

    Altium Capital Management, LP

     

     

     

     

    By:

    /s/ Jacob Gottlieb

     

    Name:

    Jacob Gottlieb

     

    Title:

    CEO

     

     

     

     

    Altium Growth Fund, LP

     

     

     

     

    By: Altium Growth GP, LLC

     

    Its: General Partner

     

     

     

     

    Signature:

    /s/ Jacob Gottlieb

     

    Name:

    Jacob Gottlieb

     

    Title:

    Managing Member of Altium Growth GP, LLC

     

     

     

     

    Altium Growth GP, LLC

     

     

     

     

    By:

    /s/ Jacob Gottlieb

     

    Name:

    Jacob Gottlieb

     

    Title:

    Managing Member

     

     

     

     

    Page 8 of 8

     

    EXHIBIT INDEX

     

    EXHIBIT 1:

    Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

     

     

     

    Members of Group

     

     

     

     

    Get the next $OPNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPNT

    DatePrice TargetRatingAnalyst
    12/9/2021$42.00Outperform
    Oppenheimer
    More analyst ratings

    $OPNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Opiant Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Opiant Pharmaceuticals with a rating of Outperform and set a new price target of $42.00

      12/9/21 4:54:31 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPNT
    Leadership Updates

    Live Leadership Updates

    See more
    • Deepwatch Names Mel Wesley as Chief Financial Officer

      Successful finance and cybersecurity industry veteran to support rapid growth Deepwatch, the leader in advanced managed detection and response (MDR) security, announced today the appointment of Mel Wesley as Chief Financial Officer (CFO). Wesley is a seasoned finance executive with over 25 years of experience in financial planning, analysis, and operational finance, with a proven track record of driving growth and building high-performance finance teams. For the past 18 years, he has served as CFO for publicly traded and private technology companies. As Deepwatch's CFO, Wesley will support the Company during hyper-growth while overseeing finance, legal and corporate development. This press

      2/21/23 10:00:00 AM ET
      $OPNT
      $SCOR
      $FEYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Business Services
      Consumer Discretionary
    • MindMed Strengthens Board with Appointment of Two New Independent Directors

      NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors. "We are pleased to welcome both Dr. Bruhn and Dr. Crystal to our Board. Their collective life sciences experience will be invaluable as we advance through several key product development inflection points in the com

      8/12/22 7:30:00 AM ET
      $MNMD
      $OPNT
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

      SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, busin

      1/17/22 8:50:00 AM ET
      $BYSI
      $CPRX
      $OPNT
      $PALI
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $OPNT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Deepwatch Names Mel Wesley as Chief Financial Officer

      Successful finance and cybersecurity industry veteran to support rapid growth Deepwatch, the leader in advanced managed detection and response (MDR) security, announced today the appointment of Mel Wesley as Chief Financial Officer (CFO). Wesley is a seasoned finance executive with over 25 years of experience in financial planning, analysis, and operational finance, with a proven track record of driving growth and building high-performance finance teams. For the past 18 years, he has served as CFO for publicly traded and private technology companies. As Deepwatch's CFO, Wesley will support the Company during hyper-growth while overseeing finance, legal and corporate development. This press

      2/21/23 10:00:00 AM ET
      $OPNT
      $SCOR
      $FEYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Business Services
      Consumer Discretionary
    • Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC

      CFIUS clearance represents the final required regulatory approval to complete the proposed mergerCompletion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023Indivior and Opiant continue to anticipate completing the proposed merger in the first quarter of 2023 SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the previously announced Merger Agreement (the Agreement) for Opiant to be acquired by Indivior PLC (LSE: INDV). Following the expiration of the waiti

      2/7/23 4:01:00 PM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC

      SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC (LSE: INDV). The waiting period expired on February 2, 2023, without any action taken by the Federal Trade Commission (FTC). The HSR Act is a key U.S. antitrust statute that enables the FTC and Department of Justice (DOJ) to review proposed merger transactions by requiring the parties to observe a waiting period before closing their transaction. Completion of the tr

      2/6/23 8:00:00 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Silver Gabrielle Alison returned $466,860 worth of shares to the company (23,343 units at $20.00), closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:27:04 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Collard Craig A returned $1,116,440 worth of shares to the company (55,822 units at $20.00), closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:25:03 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Ruth Matthew R. returned $638,320 worth of shares to the company (31,916 units at $20.00) and was granted 2,000 shares, closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:22:53 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPNT
    Financials

    Live finance-specific insights

    See more

    $OPNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $OPNT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $OPNT
    SEC Filings

    See more
    • Indivior PLC to Acquire Opiant Pharmaceuticals

      Indivior to acquire Opiant Pharmaceuticals for total consideration of $28.00 per share comprising of an upfront cash payment of $20.00 per share at closing plus contingent value rights (CVRs) worth up to $8.00 per share in cash, payable on achievement of certain net revenue thresholds for OPNT003Upfront payment represents a 111% premium to Opiant's closing share price of November 11, 2022, and 99% premium to Opiant's 30-day volume-weighted average share price; total consideration, inclusive of potential CVR payments, represents a premium of up to 195% and 178%, respectivelyAcquisition will expand Indivior's portfolio of addiction therapies and leverage its expertise and resources to maximize

      11/14/22 2:12:34 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior To Acquire Opiant Pharmaceuticals

      Acquisition Strengthens and Extends Indivior's Position as a Leader in Addiction Treatment Opiant Pipeline Anchored by OPNT003, an Opioid Overdose Treatment with Clinically Demonstrated Characteristics Well-Suited to Confront Illicit Synthetic Opioids Like Fentanyl Potential Annual OPNT003 Net Revenue of $150 Million to $250 Million Acquisition Expected to be Accretive to Earnings after the Second Full Year of Launch of OPNT003 Indivior to Host Investor Call at 8:00 am U.S. Eastern Today RICHMOND, Va., Nov. 14, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") and Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) ("Opiant") today announced that the companies have entered

      11/14/22 2:10:00 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022

      SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant" or "Company") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended September 30, 2022, after the financial markets close on Monday, November 14, 2022.   The Company's management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Monday, November 14, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13732765. To access the live webcast, please visit h

      10/27/22 4:05:00 PM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Opiant Pharmaceuticals Inc. (Amendment)

      SC 13G/A - OPIANT PHARMACEUTICALS, INC. (0001385508) (Subject)

      2/15/23 1:19:28 PM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Opiant Pharmaceuticals Inc.

      SC 13G - OPIANT PHARMACEUTICALS, INC. (0001385508) (Subject)

      11/28/22 4:07:39 PM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Opiant Pharmaceuticals Inc. (Amendment)

      SC 13D/A - OPIANT PHARMACEUTICALS, INC. (0001385508) (Subject)

      6/17/22 4:53:53 PM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OPVEE issued to OPIANT PHARMACEUTICALS INC

      Submission status for OPIANT PHARMACEUTICALS INC's drug OPVEE (ORIG-1) with active ingredient NALMEFENE has changed to 'Approval' on 05/22/2023. Application Category: NDA, Application Number: 217470, Application Classification: Type 3 - New Dosage Form

      5/24/23 11:39:07 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 22, 2023 - FDA Approves Prescription Nasal Spray to Reverse Opioid Overdose

      For Immediate Release: May 22, 2023 Today, the U.S. Food and Drug Administration approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. This is the first FDA approval of nalmefene hydrochloride nasal spray for health care and community use. “The agency continues to advance the FDA

      5/22/23 4:58:14 PM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OPVEE (nalmefene) issued to OPIANT PHARMACEUTICALS INC

      Submission status for OPIANT PHARMACEUTICALS INC's drug OPVEE (nalmefene) (ORIG-1) with active ingredient OPVEE (nalmefene) has changed to 'Approval' on 05/22/2023. Application Category: NDA, Application Number: 217470, Application Classification: Type 3 - New Dosage Form

      5/22/23 4:51:13 PM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Opiant Pharmaceuticals Inc.

      15-12G - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)

      3/13/23 6:15:56 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Opiant Pharmaceuticals Inc.

      EFFECT - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)

      3/10/23 12:15:14 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Opiant Pharmaceuticals Inc.

      EFFECT - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)

      3/10/23 12:15:06 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care